TY - JOUR
T1 - Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk
T2 - Results from the Prostate Cancer Prevention Trial
AU - Tang, Li
AU - Platek, Mary E.
AU - Yao, Song
AU - Till, Cathee
AU - Goodman, Phyllis J.
AU - Tangen, Catherine M.
AU - Wu, Yue
AU - Platz, Elizabeth A.
AU - Neuhouser, Marian L.
AU - Stanczyk, Frank Z.
AU - Reichardt, Juergen K.V.
AU - Santella, Regina M.
AU - Hsing, Ann
AU - Figg, William D.
AU - Lippman, Scott M.
AU - Thompson, Ian M.
AU - Ambrosone, Christine B.
N1 - Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press. All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Substantial preclinical data suggest estrogen's carcinogenic role in prostate cancer development; however, epidemiological evidence based on circulating estrogen levels is largely null. Compared with circulating estrogen, the intraprostatic estrogen milieu may play a more important role in prostate carcinogenesis. Using a nested case-control design in the Prostate Cancer Prevention Trial (PCPT), we examined associations of genetic variants of genes that are involved in estrogen synthesis, metabolism and function with prostate cancer risk. A total of 25 potentially functional single nucleotide polymorphisms (SNPs) in 13 genes (PGR, ESR1, ESR2, CYP17A1, HSD17B1, CYP19A1, CYP1A1, CYP1B1, COMT, UGT1A6, UGT1A10, UGT2B7, UGT2B15) were examined in whites only. Controls (n = 1380) were frequency matched to cases on age, PCPT treatment arm, and family history (n = 1506). Logistic regression models adjusted for age and family history were used to estimate odds ratios (OR) and 95% confidence intervals (CI) separately in the placebo and finasteride arms. SNPs associated with prostate cancer risk differed by treatment arm. The associations appeared to be modified by circulating estrogen and androgen levels. CYP19A1 was the only gene harboring SNPs that were significantly associated with risk in both the placebo and finasteride arms. Haplotype analysis with all three CYP19A1 SNPs genotyped (rs700518, rs2445765, rs700519) showed that risk-allele haplotypes are associated with the increased prostate cancer risk in both arms when comparing with the non-risk allele haplotype. In conclusion, associations between SNPs in estrogen-related genes and prostate cancer risk are complex and may be modified by circulating hormone levels and finasteride treatment.
AB - Substantial preclinical data suggest estrogen's carcinogenic role in prostate cancer development; however, epidemiological evidence based on circulating estrogen levels is largely null. Compared with circulating estrogen, the intraprostatic estrogen milieu may play a more important role in prostate carcinogenesis. Using a nested case-control design in the Prostate Cancer Prevention Trial (PCPT), we examined associations of genetic variants of genes that are involved in estrogen synthesis, metabolism and function with prostate cancer risk. A total of 25 potentially functional single nucleotide polymorphisms (SNPs) in 13 genes (PGR, ESR1, ESR2, CYP17A1, HSD17B1, CYP19A1, CYP1A1, CYP1B1, COMT, UGT1A6, UGT1A10, UGT2B7, UGT2B15) were examined in whites only. Controls (n = 1380) were frequency matched to cases on age, PCPT treatment arm, and family history (n = 1506). Logistic regression models adjusted for age and family history were used to estimate odds ratios (OR) and 95% confidence intervals (CI) separately in the placebo and finasteride arms. SNPs associated with prostate cancer risk differed by treatment arm. The associations appeared to be modified by circulating estrogen and androgen levels. CYP19A1 was the only gene harboring SNPs that were significantly associated with risk in both the placebo and finasteride arms. Haplotype analysis with all three CYP19A1 SNPs genotyped (rs700518, rs2445765, rs700519) showed that risk-allele haplotypes are associated with the increased prostate cancer risk in both arms when comparing with the non-risk allele haplotype. In conclusion, associations between SNPs in estrogen-related genes and prostate cancer risk are complex and may be modified by circulating hormone levels and finasteride treatment.
UR - http://www.scopus.com/inward/record.url?scp=85044470159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044470159&partnerID=8YFLogxK
U2 - 10.1093/carcin/bgx144
DO - 10.1093/carcin/bgx144
M3 - Article
C2 - 29228205
AN - SCOPUS:85044470159
SN - 0143-3334
VL - 39
SP - 125
EP - 133
JO - Carcinogenesis
JF - Carcinogenesis
IS - 2
ER -